Adicet Bio Q4 net loss $0.32/share, cash $176.3M; expects ADI-001 LN data in 1H25

Adicet Bio, Inc.

Q4 2024 net loss $28.7M ($0.32/share) vs. $29.5M ($0.69/share) in Q4 2023; full year net loss $117.1M.
Cash, cash equivalents and short-term investments $176.3M as of Dec 31, 2024; expected to fund ops into 2H26.
Phase 1 trial of ADI-001 in autoimmune diseases: LN patient preliminary data expected 1H25; enrollment for SLE, SSc, IIM, SPS to start 2Q25.
ADI-270 Phase 1 in ccRCC: preliminary data expected 1H25; first patient dosed Dec 2024.
Received FDA Fast Track Designation for ADI-001 in refractory SLE with extrarenal involvement and SSc (Feb 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.